Petrolimex Insurance Corporation (HOSE:PGI)

CTI BioPharma Income Statement

Financials in millions VND. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Premiums & Annuity Revenue	2,989,914	2,922,177	2,757,256	2,675,108	2,650,843	2,521,503
Total Interest & Dividend Income	65,002	80,524	121,644	35,173	47,919	48,352
Gain (Loss) on Sale of Investments	41,852	41,852	5,464	19,888	46,569	29,003
Other Revenue	464,491	496,180	468,902	395,755	380,807	399,421
Total Revenue	3,561,259	3,540,733	3,353,266	3,125,924	3,126,138	2,998,278
Revenue Growth (YoY)	-0.07%	5.59%	7.27%	-0.01%	4.26%	12.06%
Policy Benefits	1,399,339	1,412,465	1,344,666	1,249,311	1,074,391	1,128,320
Policy Acquisition & Underwriting Costs	248,607	238,475	222,465	221,702	255,896	237,918
Depreciation & Amortization	57,913	57,913	50,902	42,157	38,442	49,380
Selling, General & Administrative	229,065	211,619	205,059	195,910	156,349	129,689
Other Operating Expenses	955,886	940,314	912,043	919,448	929,825	999,349
Total Operating Expenses	3,288,523	3,258,499	3,062,394	2,889,667	2,678,137	2,766,276
Operating Income	272,736	282,235	290,872	236,257	448,000	232,002
Interest Expense	-11,858	-15,189	-7,167	-	-24,319	-19,528
Currency Exchange Gain (Loss)	2,654	2,654	-88.79	5,486	-	-
Other Non Operating Income (Expenses)	29,152	20,115	-4,320	10,728	2,671	4,481
EBT Excluding Unusual Items	292,684	289,814	279,296	252,470	426,352	216,955
Gain (Loss) on Sale of Assets	1,377	1,377	4,380	213.31	-	-
Pretax Income	294,061	291,191	283,677	252,684	426,352	216,955
Income Tax Expense	60,381	58,951	54,590	48,958	82,572	41,494
Net Income	233,680	232,241	229,086	203,726	343,780	175,461
Preferred Dividends & Other Adjustments	-	-	56,405	44,940	79,392	36,087
Net Income to Common	233,680	232,241	172,681	158,787	264,389	139,375
Net Income Growth	-0.67%	1.38%	12.45%	-40.74%	95.93%	7.90%
Shares Outstanding (Basic)	111	111	111	111	111	111
Shares Outstanding (Diluted)	111	111	111	111	111	111
EPS (Basic)	2107.19	2094.20	1557.13	1431.84	2384.10	1256.79
EPS (Diluted)	2106.98	2094.00	1557.00	1431.84	2384.10	1256.79
EPS Growth	30.65%	34.49%	8.74%	-39.94%	89.70%	4.61%
Free Cash Flow	-202,620	163,663	28,746	233,902	-20,476	72,608
Free Cash Flow Per Share	-1827.10	1475.81	259.21	2109.19	-184.64	654.73
Dividend Per Share	1200.000	1200.000	1200.000	-	640.000	960.000
Dividend Growth	-	-	-	-	-33.33%	-7.69%
Operating Margin	7.66%	7.97%	8.67%	7.56%	14.33%	7.74%
Profit Margin	6.56%	6.56%	5.15%	5.08%	8.46%	4.65%
Free Cash Flow Margin	-5.69%	4.62%	0.86%	7.48%	-0.66%	2.42%
EBITDA	312,055	319,921	343,274	278,415	486,442	281,382
EBITDA Margin	8.76%	9.04%	10.24%	8.91%	15.56%	9.38%
D&A For EBITDA	39,319	37,686	52,401	42,157	38,442	49,380
EBIT	272,736	282,235	290,872	236,257	448,000	232,002
EBIT Margin	7.66%	7.97%	8.67%	7.56%	14.33%	7.74%
Effective Tax Rate	20.53%	20.24%	19.24%	19.38%	19.37%	19.13%
Revenue as Reported	3,418,358	3,418,358	3,226,158	3,070,863	3,031,650	-

Source: S&P Global Market Intelligence. Insurance template. Financial Sources.